There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.
A team led by researchers at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients' brain tumors.
Cells produce exosomes, the nano-sized biological capsules, to protect and courier delicate molecules across the body. The capsules are hard enough to resist enzymatic breakdown and acidic and temperature fluctuations in the bloodstream and gut, which makes them a major candidate for drug delivery.
Researchers have developed a new method that offers novel insights into cancer biology by enabling them to unravel how single cells absorb fatty acids.
A promising treatment for melanoma and other types of cancers is neoadjuvant immune checkpoint blockade (ICB).
A new study coordinated by the University of Trento could have identified the cell of origin of medulloblastoma—a malignant tumor in children that affects the central nervous system. In this study, scientists have used organoids to replicate the tumor tissue, for the first time.
Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted by natural killer (NK) cells, they are able to evade immune attack by releasing the TFG-β signaling protein, which blocks NK cell activity.
Medulloblastoma is a rare but devastating childhood brain cancer. This cancer can spread through the spinal fluid and be deposited elsewhere in the brain or spine.
One of the hallmarks of Glioblastoma (GBM), the most aggressive type of brain cancer, is its high invasive capacity, which leads to its expansion into the normal brain tissue.
Researchers at Tel Aviv University have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers.
Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies.
Scientists have designed a new targeted therapy, known as POMHEX, which inhibits vital metabolic pathways in tumor cells containing specific genetic defects.
Researchers have shown that the advanced CRISPR/Cas9 system is extremely effective in curing metastatic cancers.
For many cancers, doctors are increasingly looking to the DNA that solid tumors shed into the blood stream to help with diagnosis and monitoring.
Researchers have designed a laboratory test that can precisely examine the deadliest cells found in the most common and aggressive type of brain cancer.
Scientists have identified key molecules that mediate radioresistance in glioblastoma multiforme; these molecules are a potential target for the treatment of this brain cancer.
Interpreting the particular mutations that play a role in different forms of cancer is crucial to enhance diagnosis and treatment.
Australian researchers have discovered that removing copper from the blood can destroy some of the deadliest cancers that are resistant to immunotherapy using models of the disease.
Brain tumors are typically diagnosed using MRI imaging, as taking a sample for a tissue biopsy is risky and may not be possible due to tumor location or a patient's poor health conditions.
More than 200 genes with novel and known roles in glioblastoma - the most aggressive type of brain cancer - offer promising new drug targets.
Rare inherited mutations in the body's master regulator of the DNA repair system – the TP53 gene – can leave people at a higher risk of developing multiple types of cancer over the course of their lives.